Fig. 1From: Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapyStudy design. aPatient numbers refer to the breast cancer modified intent-to-treat population. IV, intravenously; SC, subcutaneouslyBack to article page